Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
BMJ Open · 2024
DOI: 10.1136/bmjopen-2023-080606 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ Open, 2024. Verfasst von Tommaso Clemente und 19 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy clemente.tommaso@hsr.it. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). Key research purposes include the evaluation of residual susceptibility to specific antiretrovirals and the validation of treatment and monitoring strategies in this population.
Participants
The PRESTIGIO Registry collects annual plasma and peripheral blood mononuclear cell samples and demographic, clinical, virological, treatment and laboratory data from PLWH followed at 39 Italian clinical centres and characterised by intermediate-to-high genotypic resistance to ≥1 nucleoside reverse transcriptase inhibitors, ≥1 non-nucleoside reverse transcriptase inhibitors, ≥1 protease inhibitors, plus either intermediate-to-high genotypic resistance to ≥1 integrase strand transfer inhibitors (INSTIs) or history of virological failure to an INSTI-containing regimen. To date, 229 people have been recorded in the cohort. Most of the data are collected from the date of the first evidence of 4DR (baseline), with some prebaseline information obtained retrospectively. Samples are collected from the date of enrollment in the registry. Findings to date The open-ended cohort has been used to assess (1) prognosis in terms of survival or development of AIDS-related or non-AIDS-related clinical events; (2) long-term efficacy and safety of different antiretroviral regimens and (3) virological and immunological factors predictive of clinical outcome and treatment efficacy, especially through analysis of plasma and cell samples. Future plans The registry can provide new knowledge on how to implement an integrated approach to study PLWH with documented resistance to the four main antiretroviral classes, a population with a limited number of individuals characterised by a high degree of frailty and complexity in therapeutic management. Given the scheduled annual updates of PLWH data, the researchers who collaborate in the registry can send study proposals at any time to the steering committee of the registry, which evaluates every 3 months whether the research studies can be conducted on data and biosamples from the registry and whether they are aimed at a better understanding of a specific health condition, the emergence of comorbidities or the effect of potential treatments or experimental drugs that may have an impact on disease progression and quality of life. Finally, the research studies should aim to be inclusive, innovative and in touch with the communities and society as a whole. Trial registration number NCT04098315 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vita-Salute San Raffaele University, Milan, Italy clemente.tommaso@hsr.it.
- Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy.
- Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
- Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
- Infectious Diseases Unit, Department of Molecular Medicine, Padua University Hospital, Padua, Italy.
ORCID-Profile: Tommaso Clemente, Laura Galli, Riccardo Lolatto, Roberta Gagliardini, Filippo Lagi, Micol Ferrara, Anna Maria Cattelan, Emanuele Focà, Antonio Di Biagio, Adriana Cervo, Leonardo Calza, Franco Maggiolo, Giulia Marchetti, Giovanni Cenderello, Stefano Rusconi, Maurizio Zazzi, Maria Mercedes Santoro, Vincenzo Spagnuolo, Antonella Castagna
Zitieren
APA
Clemente, T., Galli, L., Lolatto, R., Gagliardini, R., Lagi, F., Ferrara, M., Cattelan, A. M., Focà, E., Di Biagio, A., Cervo, A., Calza, L., Maggiolo, F., Marchetti, G., Cenderello, G., Rusconi, S., Zazzi, M., Santoro, M. M., Spagnuolo, V., Castagna, A., & PRESTIGIO Study Group (2024). Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080606
Vancouver
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, et al. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080606
BibTeX
@article{Clemente2024,
author = {Clemente, Tommaso and Galli, Laura and Lolatto, Riccardo and Gagliardini, Roberta and Lagi, Filippo and Ferrara, Micol and Cattelan, Anna Maria and Focà, Emanuele and Di Biagio, Antonio and Cervo, Adriana and Calza, Leonardo and Maggiolo, Franco and Marchetti, Giulia and Cenderello, Giovanni and Rusconi, Stefano and Zazzi, Maurizio and Santoro, Maria Mercedes and Spagnuolo, Vincenzo and Castagna, Antonella and PRESTIGIO Study Group, PRESTIGIO Study Group},
title = {Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors},
journal = {BMJ Open},
year = {2024},
doi = {10.1136/bmjopen-2023-080606}
}
EUVIMED